ArticleScientific reports2025
The effect of PDLIM7 on cell proliferation, migration, and drug sensitivity in clear cell renal cell carcinoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Spatially-resolved subtype progression reveals metabolic vulnerabilities in pancreatic ductal adenocarcinoma.Molecular cancer · 2026Article
- Osmotic Tension Asymmetry Drives Electrotactic Migration via PDLIM7-Polarized Microfilament Coordination in Breast Cancer Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A case report: Synchronous occurrence of clear cell renal cell carcinoma and low-malignant-potential multicystic renal tumor within the same kidney.Urology case reports · 2026Article
- Decoding early lung adenocarcinoma progression by single-cell and spatial transcriptomics reveals a CMA-related prognostic signature.Frontiers in immunology · 2026Article
- Case Report: Late simultaneous metastasis of renal clear cell carcinoma to the ampulla and breast.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Clear cell renal cell carcinoma (ccRCC) is a subtype of renal cancer primarily originating from renal tubular epithelial cells. The absence of effective treatments has contributed to its poor prognosis. PDLIM7 is a protein containing PDZ and LIM structural domains, which performs varied functions through interactions with different proteins. To elucidate the role of PDLIM7 in ccRCC, we aimed to investigate its potential functions in relation to drug sensitivity. We analyzed multiple databases to assess the relationship between PDLIM7 expression and clinicopathological features, and conducted survival prognosis analysis. The expression level of PDLIM7 was validated through Western blotting and immunohistochemistry (IHC). We determined the effects and mechanisms of PDLIM7 on cancer cell proliferation, migration, and invasion through cloning assays, scratch assays, and Transwell assays. The functions and potential mechanisms of action of PDLIM7 were analyzed using gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) enrichment analyses. Its relationship with drug sensitivity was predicted utilizing the CellMiner database. Our study demonstrated that elevated PDLIM7 expression in ccRCC tissues and cell lines is significantly associated with the prognosis of patients with ccRCC. The knockdown of PDLIM7 markedly reduced the activity of ccRCC cells. KEGG and GO functional enrichment analyses indicated that PDLIM7 is implicated in various biological functions and signaling pathways. Higher levels of PDLIM7 are associated with increased sensitivity to a range of therapeutic agents. In conclusion, PDLIM7 is highly expressed in ccRCC and functions as an oncogene; its knockdown significantly inhibits the activity of ccRCC cells. PDLIM7 may serve as a prognostic marker for ccRCC and represents a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.